Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxidative Phosphorylation Targeting in Malignant Glioma Using Metformin plus Radiotherapy and Temozolomide
2024-511026-31-01Phase 2Authorised
- Sponsor
- Hôpital Foch
- Start
- Oct 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of temozolomide and metformin in glioblastoma (GBM), sponsored by Hôpital Foch. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
temozolomidemetformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-511026-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511026-31-01.